title: The Cost-Effectiveness OF Canagliflozin (Cana) Versus Dapagliflozin (Dapa) In Patients With Type 2 Diabetes Mellitus (T2dm) With Inadequate Control On Metformin (Met) Monotherapy In The United Kingdom.
authors.affiliation: Janssen-Cilag UK, High Wycombe, UK.
authors.forename: M
authors.initials: M
authors.lastname: Schroeder
authors.affiliation: The Swedish Institute for Health Economics (IHE), Lund, Sweden.
authors.forename: P
authors.initials: P
authors.lastname: Johansen
authors.affiliation: Janssen-Cilag UK, High Wycombe, UK.
authors.forename: G
authors.initials: G
authors.lastname: Thompson
authors.affiliation: The Swedish Institute for Health Economics, Lund, Sweden.
authors.forename: M
authors.initials: M
authors.lastname: Willis
authors.affiliation: Janssen Global Services, LLC, Raritan, NJ, USA.
authors.forename: C
authors.initials: C
authors.lastname: Neslusan